Mercer Island-based Concure Oncology has secured another $2 million in capital to further grow its organization and train clinicians across the country to bring Concure’s new radiation treatment option to more women facing early-stage breast cancer, the company recently announced in a news release. The company’s Breast Microseed Treatment for post-lumpectomy patients is a one-time, one-hour procedure, as opposed to conventional radiation that might last three to six weeks and require daily visits to a radiation facility.

The procedure involves the placement of tiny, low dose-rate brachytherapy sources, or Microseeds, into the breast tissue, which release a safe, effective dose of radiation for two to three months to the immediate area surrounding the lumpectomy site. Once fully released, the seeds become inert, with no radioactivity remaining, the company said in a news release.